Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Go back to Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 1.84 +0.01 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.83 | 52 Week High | $0.03 | |||
| Open | $1.74 | 52 Week Low | $0.01 | |||
| Day High | $1.87 | P/E | N/A | |||
| Day Low | $1.73 | EPS | $0.00 | |||
| Volume | 2,300,369 | |||||
| (NASDAQ: OTLKW) | Delayed: 0.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.03 | 52 Week High | $ | |||
| Open | $6.93 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.03 | EPS | $ | |||
| Volume | 176,912 | |||||
